Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S, Pérez-Vélez CM, Pagano M, Becerra MC, Cohen T (2014) Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet 383(9928):1572–1579

Article  PubMed  PubMed Central  Google Scholar 

Jenkins HE, Yuen CM (2018) The burden of multidrug-resistant tuberculosis in children. Int J Tuberc Lung Dis 22(5):3–6

Article  CAS  PubMed  Google Scholar 

Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J et al (2020) Treatment of highly Drug-Resistant pulmonary tuberculosis. N Engl J Med 382(10):893–902

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, Samoilova A, Skornykova S, Tudor E, Variava E et al (2022) Bedaquiline-Pretomanid-Linezolid regimens for Drug-Resistant tuberculosis. N Engl J Med 387(9):810–823

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiong YJ, Xiao Y, Xie L, Gao L, Han Y, Huang PF, Liu S, Liang YX, Wang H (2024) Contezolid for the treatment of Drug-Resistant tuberculosis in China: A clinical case series. Infect Drug Resist 17:3491–3499

Article  PubMed  PubMed Central  Google Scholar 

Wang J, Ma L (2023) Tuberculosis patients with special clinical conditions treated with contezolid: three case reports and a literature review. Front Med (Lausanne) 10:1265923

Article  PubMed  Google Scholar 

Sarathy J, Blanc L, Alvarez-Cabrera N, O’Brien P, Dias-Freedman I, Mina M, Zimmerman M, Kaya F, Ho Liang HP, Prideaux B et al (2019) Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations. Antimicrob Agents Chemother 63(5)

Zhang Y, Lai Y, Zhou S, Ran T, Zhang Y, Zhao Z, Feng Z, Yu L, Xu J, Shi K et al (2024) Inhibition of M. tuberculosis and human ATP synthase by BDQ and TBAJ-587. Nature 631(8020):409–414

Article  CAS  PubMed  Google Scholar 

Madzgharashvili T, Salindri AD, Magee MJ, Tukvadze N, Avaliani Z, Blumberg HM, Kempker RR, Lomtadze N (2021) Treatment outcomes among pediatric patients with highly Drug-Resistant tuberculosis: the role of new and repurposed Second-Line tuberculosis drugs. J Pediatr Infect Dis Soc 10(4):457–467

Article  CAS  Google Scholar 

Khoshnood S, Taki E, Sadeghifard N, Kaviar VH, Haddadi MH, Farshadzadeh Z, Kouhsari E, Goudarzi M, Heidary M (2021) Mechanism of action, resistance, synergism, and clinical implications of Delamanid against Multidrug-Resistant Mycobacterium tuberculosis. Front Microbiol 12:717045

Article  PubMed  PubMed Central  Google Scholar 

Blair HA, Scott LJ (2015) Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs 75(1):91–100

Article  CAS  PubMed  Google Scholar 

Jiang G, Liu R, Xue Y, Ge Q, Nie L, Lv Z, Kong Z, Shi J, Chen H, Li H et al (2025) Contezolid harbored equivalent efficacy to linezolid in tuberculosis T reatment in a prospective and randomized early bactericidal activity Study. IDR, 18:261–268